| Description | This product is a human neutralizing antibody binding HIV-1 gp120, termed ACS101. Its epitope is CD4-binding site (CD4bs) on the gp120 subunit, which is an attractive target for HIV-1 immunogen design. ACS101 exhibits moderate neutralization breadth and potency. This product has been detected using Enzyme-linked immunosorbent assay, Bio-layer interferometry and Neutralization assay. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | HIV1 |
| Epitope | CD4-binding site |
| Expression Species | HEK293F or CHO cell line |
| Conjugation | Unconjugated |
| Purity | >95% |
| Endotoxin | <1 EU/mg |
| Form | Liquid |
| Purification | Protein A purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics. |
| Application | ELISA; Neut; BLI |
| Application Notes | Bio-layer interferometry (BLI): The antibody was diluted to 10 µg/mL in reaction buffer and immobilized onto the AHI probes for 300 s. Neutralization assay: ACS101 neutralized 55/147 of the tested viruses (∼37%) with a geometric mean IC50 of 3.3 μg/ml. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | HIV1 gp120 |
| Alternative Name | Human immunodeficiencyvirus-1 glycoprotein 120 |
| Research Area | Infectious Disease |
| Related Disease | Acquired Immune Deficiency Syndrome |
